THERIVA BIOLOGICS INC (TOVX) Stock Analyst Earnings Estimates
NYSEARCA:TOVX - American Stock Exchange - US87164U5083 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 110.11% | N/A 185.64% | N/A 94.37% | |||||||||||
| EBITDA YoY % growth | -20.48M | -40.91M -99.76% | -39.09M 4.45% | -26M 33.49% | -17.3M 33.46% | -15.42M 10.87% | -9.96M 35.41% | -14.18M -42.37% | -21.29M -50.14% | -21.296M -0.03% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -20.5M | -40.98M -99.90% | -39.25M 4.22% | -26.25M 33.12% | -17.57M 33.07% | -15.66M 10.87% | -10.16M 35.12% | -14.27M -40.45% | -21.38M -49.82% | -21.431M -0.24% | N/A -9.70% | N/A -57.16% | N/A -12.91% | N/A -13.09% | N/A 33.31% | N/A 68.22% | N/A 801.84% | N/A 166.89% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -2,800.00 | -4,375.00 -56.25% | -2,537.50 42.00% | -1,487.50 41.38% | -749.96 49.58% | -232.50 69.00% | -152.50 34.41% | -52.50 65.57% | -31.75 39.52% | -29.25 7.87% | N/A 7.59% | N/A 30.19% | N/A 16.22% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q4 / 24 | |
|---|---|
| EPS Q2Q % growth | -6.49 23.68% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -8.364M -34.53% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -6.81 -43.37% | -6.38 | -0.43 | -6.82% |
| Q2 2024 Q2Q % growth | 96.64% | -0.29 | % | |
| Q1 2024 Q2Q % growth | -7.50 | -8.67 | 1.17 | 13.49% |
| Q4 2023 Q2Q % growth | -8.50 -3.03% | -10.46 | 1.96 | 18.70% |
| Q3 2023 Q2Q % growth | -4.75 42.42% | -9.56 | 4.81 | 50.33% |
| Q2 2023 Q2Q % growth | -8.50 -9.68% | -9.18 | 0.68 | 7.41% |
| Q1 2023 Q2Q % growth | -7.50 | -8.16 | 0.66 | 8.09% |
| Q4 2022 Q2Q % growth | -8.25 17.50% | -8.54 | 0.29 | 3.42% |
| Q3 2022 Q2Q % growth | -8.25 -65.00% | -10.07 | 1.82 | 18.09% |
| Q2 2022 Q2Q % growth | -7.75 -55.00% | -8.93 | 1.18 | 13.17% |
| Q1 2022 Q2Q % growth | -7.50 76.92% | -7.65 | 0.15 | 1.96% |
| Q4 2021 Q2Q % growth | -10.00 71.43% | -7.65 | -2.35 | -30.72% |
| Q3 2021 Q2Q % growth | -5.00 85.71% | -6.38 | 1.38 | 21.57% |
| Q2 2021 Q2Q % growth | -5.00 87.50% | -5.10 | 0.10 | 1.96% |
| Q1 2021 Q2Q % growth | -32.50 23.53% | -5.10 | -27.40 | -537.25% |
| Q4 2020 Q2Q % growth | -35.00 26.32% | -20.40 | -14.60 | -71.57% |
| Q3 2020 Q2Q % growth | -35.00 53.33% | -43.35 | 8.35 | 19.26% |
| Q2 2020 Q2Q % growth | -40.00 27.27% | -40.80 | 0.80 | 1.96% |
| Q1 2020 Q2Q % growth | -42.50 22.73% | -68.85 | 26.35 | 38.27% |
| Q4 2019 Q2Q % growth | -47.50 | -58.65 | 11.15 | 19.01% |
| Q3 2019 Q2Q % growth | -75.00 | -58.65 | -16.35 | -27.88% |
| Q2 2019 Q2Q % growth | -55.00 | -58.65 | 3.65 | 6.22% |
| Q1 2019 Q2Q % growth | -55.00 | -58.65 | 3.65 | 6.22% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -2093.1% | 0% | -2400% |
| Revenue | N/A | N/A | N/A | N/A |